Announced
Completed
Financials
Tags
prescription drugs
Reverse Takeover
Domestic
Majority
Acquisition
Private
Single Bidder
Pharmaceuticals
United States
Friendly
De-SPAC
Completed
Synopsis
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, went public via a merger with Big Cypress Acquisition, a SPAC, in a c.$325m deal. “SAB met or exceeded our criteria, demonstrating de-risked early development processes, clinical proof-of-concept, therapeutic targets with large unmet needs and what we expect to be manageable Phase 3 trials, high-value indications, and the ability to efficiently put additional capital to work advancing a high potential pipeline," Sam Reich, Big Cypress Acquisition CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.